CATALYSTYahoo Finance • 20h ago
Hyperfine Reports Record Preliminary Q3 Revenue of $6 Million, Up 53% SequentiallyYahoo Finance report covering Hyperfine Inc. (Class A) (HYPR) market action, institutional positioning, and fundamental catalysts.
Why HYPR Stock advanced +0.99% Today — RQD Quant Desk Flash
$0.72 +0.99% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $0.72
Hyperfine Inc. (Class A) (HYPR) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $76.1M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on HYPR Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is HYPR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Hyperfine Inc. (Class A) (NASDAQ: HYPR) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $0.72 (+0.99% 1D, market cap $76.1M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, HYPR ranks #512 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does HYPR compare to OM and ECOR in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), HYPR carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of 49.8%, and ROIC of -35.0%. By comparison, OM (Outset Medical Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -28.0%, cap $75.8M) and ECOR (electroCore Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $67.8M). Among the 5-stock peer group, HYPR leads on earnings multiple (N/A) while OM leads on capital efficiency (-28.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for HYPR?
▼
Per HYPR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001833769), Hyperfine Inc. (Class A) generated $13.6M in revenue (+5.2% YoY), -$35.6M in net income, and -$29.1M in free cash flow against $55.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $0.72 (-0.01%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.8% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-8.3% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for HYPR)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (38/100 Composite)
🔍 WHY HYPR SCORES 38/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (29% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 6/9
▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (21% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 49.8% Gross Margin
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$0.85-9.4% Next Q
46
Q2 (-2Q)Grade D$0.77-2.6% Next Q
43
Q3 (-1Q)Grade D$0.75-4% Next Q
41
CurrentGrade D-$0.72-7.8% Hist 90D α
38
Trajectory: D (46) → D- (38)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a HYPR Turnaround Squeeze
While HYPR currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($0.81) and Max Pain ($0.76) forces dealer call-delta covering toward $2.03.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $HYPR• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “HYPR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why HYPR Stock advanced +0.99% Today — RQD Quant Desk Flash
Hyperfine Inc. (Class A) (HYPR) advanced +0.99% to $0.72, trading at 2% of its 52-week range ($0.7 – $1.93). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($0.7 – $1.93) with RSI-14 at 40.2 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $0.72 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 49.8% gross margin and $0 annual free cash flow.
Live HYPR Headlines & Catalysts
MARKET WIREStockInvest.us • 23h ago
Hyperfine Stock Price Forecast. Should You Buy HYPR?StockInvest.us report covering Hyperfine Inc. (Class A) (HYPR) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 1d ago
Hyperfine, Inc. Estimates – NASDAQ:HYPRTradingView report covering Hyperfine Inc. (Class A) (HYPR) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 1d ago
Full Transcript: Hyperfine Q2 2026 Earnings CallBenzinga report covering Hyperfine Inc. (Class A) (HYPR) market action, institutional positioning, and fundamental catalysts.
MARKET WIREQuiver Quantitative • 1d ago
Hyperfine Reports Preliminary Q3 Revenue of Approximately $6.0 Million | HYPR Stock NewsQuiver Quantitative report covering Hyperfine Inc. (Class A) (HYPR) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
Six German symphony performances bring brain scans onstageStock Titan report covering Hyperfine Inc. (Class A) (HYPR) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 1d ago
12 Health Care Stocks Moving In Wednesday's Pre-Market SessionBenzinga report covering Hyperfine Inc. (Class A) (HYPR) market action, institutional positioning, and fundamental catalysts.
MARKET WIREhttps://www.siam.in/ • 1d ago
Hyperfine (HYPR) Holds Near $0.72 as Traders Eye $0.68 Support - Inverse ETF Flowhttps://www.siam.in/ report covering Hyperfine Inc. (Class A) (HYPR) market action, institutional positioning, and fundamental catalysts.
MARKET WIREBenzinga • 6d ago
Lucid Capital Markets Initiates Coverage On Hyperfine with Buy Rating, Announces Price Target of $2Lucid Capital Markets analyst Alex Nowark initiates coverage on Hyperfine (NASDAQ:HYPR) with a Buy rating and announces Price Target of $2.
CATALYSTYahoo • 11d ago
Hyperfine Advances International Swoop System Model 2 Rollout and Highlights the Role of Portable MRI in Brain Health AwarenessGUILFORD, Conn., October 22, 2026--CE mark and UKCA approvals support Swoop system Model 2 expansion as Hyperfine highlights portable MRI in brain health awareness efforts.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring HYPR)
- ✓Walkthrough of HYPR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
HYPR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -60.22%🛡️ HOLDING TREND SUPPORT
2026-11-03O $0.75H $0.75L $0.72C $0.72VOL 565.6K
RES: $1.05SUP: $0.64SMA50: $0.81SMA200: $1.13
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
HYPR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +5.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on HYPR today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for HYPR. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for HYPR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HYPR)
Health Care Rank #512 of 1016
⚔️ OM vs HYPR Full Matrix →
1. Head-to-Head Health Care Peer Comparison (HYPR vs. OM, ECOR, STXS, NRXS)
Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (26 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Hyperfine Inc. (Class A) (HYPR) ranks #512 by composite RQD confidence (38/100, grade D-) and #687 by equity capitalization ($76.1M). Within this direct 5-issuer industry benchmark cohort, HYPR leads on earnings valuation at N/A trailing P/E, while OM leads on capital efficiency and profitability with -28.0% ROIC and 39.1% gross margin. HYPR currently leads its immediate peer cohort in composite quantitative strength at 38/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| HYPR
ACTIVE
Hyperfine Inc. (Class A) | D- | 38/100 | — | 49.8% | -35.0% | +0.99% | $76.1M | Benchmark Subject |
| OM Outset Medical Inc. | E | 34/100 | — | 39.1% | -28.0% | -0.25% | $75.8M | /om-vs-hypr → |
| ECOR electroCore Inc. | E | 29/100 | — | 86.8% | -35.0% | -4.79% | $67.8M | /ecor-vs-hypr → |
| STXS Stereotaxis Inc. | E | 22/100 | — | 52.7% | -35.0% | +2.03% | $86.4M | /stxs-vs-hypr → |
| NRXS Neuraxis Inc. | D- | 36/100 | — | 84.2% | -35.0% | -7.43% | $89.5M | /nrxs-vs-hypr → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001833769In its most recent audited fiscal period (FY2025, filed 2025-12-31), Hyperfine Inc. (Class A) (HYPR) reported GAAP revenue of $13.6M (+5.2% vs. FY2024 revenue of $12.9M , and +22.9% cumulative change since FY2023) , GAAP net income of -$35.6M, operating cash flow of -$27.9M, and free cash flow of -$29.1M (+25.6% YoY). On the balance sheet, HYPR closed FY2025 with $55.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 6/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $13.6M | -$35.6M | -$27.9M | -$29.1M | $55.3M | $0 |
| FY2024 (FY) | 2024-12-31 | $12.9M | -$40.7M | -$38.8M | -$39.1M | $58.9M | — |
| FY2023 (FY) | 2023-12-31 | $11.0M | -$44.2M | -$41.8M | -$41.8M | — | — |
3. HYPR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs HYPR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Hyperfine Inc. (Class A) (NASDAQ: HYPR) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $0.72 (+0.99% 1D, market cap $76.1M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, HYPR ranks #512 in composite RQD confidence.
How does HYPR compare to OM and ECOR in the Health Care sector?
Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), HYPR carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of 49.8%, and ROIC of -35.0%. By comparison, OM (Outset Medical Inc.) holds a E grade (34/100 RQD, P/E N/A, ROIC -28.0%, cap $75.8M) and ECOR (electroCore Inc.) posts a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $67.8M). Among the 5-stock peer group, HYPR leads on earnings multiple (N/A) while OM leads on capital efficiency (-28.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for HYPR?
Per HYPR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001833769), Hyperfine Inc. (Class A) generated $13.6M in revenue (+5.2% YoY), -$35.6M in net income, and -$29.1M in free cash flow against $55.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is HYPR trading relative to its 50-day, 200-day, and 52-week technical levels?
HYPR last traded at $0.72 (+0.99% on volume of 198,665 shares), positioning the stock -11.11% below its 50-day simple moving average ($0.81) and -36.28% below its 200-day simple moving average ($1.13). Across its 52-week range of $0.70 to $1.93, HYPR sits at the 1.6% percentile with a 14-day RSI of 40.2 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.81).
ROARABLE RATING BRIEF • RQD 38/100 (D-)
✓ STAGE-C NUMBER FIREWALL VERIFIED
HYPR — Hyperfine Inc. (Class A): What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:45:06Z
1. Roarable Rating Brief: What This Means to a Prospective Investor
HYPR scores 38 out of 100, a letter grade of D-, with the verdict label "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are: Fundamental Cash Engine at 8/20 (ROIC -35%; FCF yield 0%), Whale 13F Flow at 6/20 (institutional accumulation and options positioning), Insider Conviction at 5/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 8/20 (beta 1.0; sector sensitivity), and Forensic Balance Sheet at 11/20 (Altman Z 2.5; Piotroski F 6/9; Debt/Equity 0.5). The weakest pillars are Insider Conviction and Whale/13F Flow, while the Forensic Balance Sheet is the strongest relative to its weight. For a prospective investor, the rating points to an operating model that is not currently self-funding: the cash-engine pillar and the 0% FCF yield indicate that the upside case depends on improvement in operating economics rather than on present cash generation. The balance-sheet pillar offers some comfort on solvency metrics, but the rating's overall verdict reflects weak flow signals and limited insider conviction.
2. Business Model, Unit Margins & SEC Financial Trajectory
Hyperfine Inc. (Class A) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry..1B. —
Revenue rose from $11.0M in FY 2023 to $13.6M in FY 2025, while net income remained negative across all three periods. Per the market data, the gross margin is 49.8%, with operating and net margins of -60% and ROIC of -35%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 6/9, with a Debt/Equity ratio of 0.5. FY 2025 cash was $35.1M against reported debt of —.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case: Revenue grew from $11.0M in FY 2023 to $13.6M in FY 2025 while the balance sheet carried $35.1M of cash against $0.0M of reported debt. With Fundamental Cash Engine at 8/20 (ROIC -35.0%, FCF yield —) and Institutional Whale Flow at 6/20, sustained execution supports upside toward the top of the $0.70 – $1.93 52-week range.
- 🐻 Primary Bear Case: Operating margin of -60% and FCF of -$29.1M in FY 2025 leave the company without a self-funding cash engine and a 0% FCF yield. Investors must weigh current valuation against -60.0% operating margins and a 1.00 macro beta if sector demand softens.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
— The Butterfly Supply-Chain Graph lists supply_chain as "NONE," with no upstream or downstream links and no sector-correlation signals. The source data therefore does not identify specific upstream suppliers, downstream customers, or second-order bottlenecks.
- Key Question #1: What are the company's specific products, customers, and revenue drivers behind the FY 2025 revenue of $13.6M?
- Key Question #2: What is the company's cash runway given FY 2025 FCF of -$29.1M against cash of $35.1M, and what is the FY 2024 cash balance comparison?
- Key Question #3: What is the status of the "record preliminary Q3 revenue" catalyst, and how does it reconcile with the reported losses?
HYPR Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Hyperfine Inc. (Class A) (HYPR) • Click "Debate This Headline" to argue it in the Roar Pit below
🟢 CATALYST Yahoo Finance • 20h ago
Hyperfine Reports Record Preliminary Q3 Revenue of $6 Million, Up 53% Sequentially Yahoo Finance report covering Hyperfine Inc. (Class A) (HYPR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE StockInvest.us • 23h ago
Hyperfine Stock Price Forecast. Should You Buy HYPR? StockInvest.us report covering Hyperfine Inc. (Class A) (HYPR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 1d ago
Hyperfine, Inc. Estimates – NASDAQ:HYPR TradingView report covering Hyperfine Inc. (Class A) (HYPR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 1d ago
Full Transcript: Hyperfine Q2 2026 Earnings Call Benzinga report covering Hyperfine Inc. (Class A) (HYPR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Quiver Quantitative • 1d ago
Hyperfine Reports Preliminary Q3 Revenue of Approximately $6.0 Million | HYPR Stock News Quiver Quantitative report covering Hyperfine Inc. (Class A) (HYPR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
Six German symphony performances bring brain scans onstage Stock Titan report covering Hyperfine Inc. (Class A) (HYPR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Benzinga • 1d ago
12 Health Care Stocks Moving In Wednesday's Pre-Market Session Benzinga report covering Hyperfine Inc. (Class A) (HYPR) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE https://www.siam.in/ • 1d ago
Hyperfine (HYPR) Holds Near $0.72 as Traders Eye $0.68 Support - Inverse ETF Flow https://www.siam.in/ report covering Hyperfine Inc. (Class A) (HYPR) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
HYPR Bull vs. Bear Conversation Board — What's Your Call at $0.72?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON HYPR 🐻 33% BEARISH CONVICTION
DE DeepValue_CFA Institutional Buy-Side 🐂 BULLISH
🎯 Target: $0.84 (+16.7%)
📌 Pinned Debate Revenue grew from $11.0M in FY 2023 to $13.6M in FY 2025 while the balance sheet carried $35.1M of cash against $0.0M of reported debt.
The street is overcomplicating Hyperfine Inc. (Class A) (HYPR). Revenue grew from $11.0M in FY 2023 to $13.6M in FY 2025 while the balance sheet carried $35.1M of cash against $0.0M of reported debt.. With an RQD score of 38/100 (D-) and Forensic Balance Sheet at 11/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $0.78.
VolSurface_Trader 🐂 BULL
Both sides have a point here — HYPR's 11/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
ME MeanReversion_88 Quantitative Statistical Arb 🐻 BEARISH
🎯 Target: $0.59 (-18.1%)
Spot @ $0.72 Operating margin of -60% and FCF of -$29.1M in FY 2025 leave the company without a self-funding cash engine and a 0% FCF yield.
Operating margin of -60% and FCF of -$29.1M in FY 2025 leave the company without a self-funding cash engine and a 0% FCF yield.. Look at the math on HYPR: paying current EV/EBITDA multiples for -35.0% ROIC and -60.0% operating margins leaves zero margin of safety if Biotechnology: Electromedical & Electrotherapeutic Apparatus demand softens. I'd wait for a retest of $0.63 before getting long.